Novel Movable Typing for Personalized Vein‐Chips in Large Scale: Recapitulate Patient‐Specific Virchow's Triad and its Contribution to Cerebral Venous Sinus Thrombosis

Zhao, Yunduo Charles; Zhang, Yingqi; Wang, Zihao; Jiang, Fan; Kyanian, Kiarash; Aye, San‐Seint‐Seint; Hong, Tianbo; Vatankhah, Parham; Nasser, Arian; Sun, Allan; Moldovan, Laura; Su, Qian P.; Cho, Ann‐Na; Wang, Yao; Passam, Freda; Ang, Timothy; Ju, Lining Arnold

doi:10.1002/adfm.202214179

Cited by 9 publications

(11 citation statements)

References 56 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We then performed stenosis test (Figure E) on the soft PDMS valves at different air compression ratios [compression ratio (CR) = 1 – volume after compression (Vc)/total air volume (Vt)], including 0 (Vc: 8 mL; Vt: 8 mL), 0.25 (Vc: 6 mL; Vt: 8 mL), 0.50 (Vc: 4 mL; Vt: 8 mL), and 0.75 (Vc: 2 mL; Vt: 8 mL). The results show that the regulated paths between the two PDMS valves are 50 (SD: 0.0), 48.85 (SD: 0.6405), 46.37 (SD: 0.4912), and 39.25 μm (SD: 0.4511) with the physiological stenosis severity ranging from 0 to 21.5%. ,, These results indicate that progressive valvular stenosis can be realized by air compression regulation.…”

Section: Resultsmentioning

confidence: 74%

“…The results show that the regulated paths between the two PDMS valves are 50 (SD: 0.0), 48.85 (SD: 0.6405), 46.37 (SD: 0.4912), and 39.25 μm (SD: 0.4511) with the physiological stenosis severity ranging from 0 to 21.5%. 2,5,10 These results indicate that progressive valvular stenosis can be realized by air compression regulation.…”

Section: ■ Materials and Methodsmentioning

confidence: 66%

“…In a prospective clinical study, by the use of the developed system, we made an optical quantitative analysis of hemodynamics under progressive valvular stenosis. Figure A shows the images of the blood flow field (flow rate: 5 μL/min; venous flow model) under progressive valvular stenosis (physiological stenosis severity from 0 to 21.5%). ,, The results of imaging analysis are shown in Figure B, from which it is clearly seen that valvular stenosis alters regular hemodynamics. ,− The light intensity contour map of the flow field (Figure C) shows that light intensity and distribution in the valvular region and microfluidic chamber are altered under valvular stenosis. Notably, there is an apparent decrease of light intensity in the valvular region, consistent with the results of finite element analysis (Figure C and Figure S1), which indicates the enhancing effect of valvular stenosis on the shear rate.…”

Section: Resultsmentioning

confidence: 99%

“…In a prospective clinical study, by the use of the developed system, we made an optical quantitative analysis of hemodynamics under progressive valvular stenosis. Figure3Ashows the images of the blood flow field (flow rate: 5 μL/ min; venous flow model) under progressive valvular stenosis (physiological stenosis severity from 0 to 21.5%) 2,5,10. The…”

mentioning

confidence: 99%

“…Valvular diseases are increasingly prevalent worldwide as a consequence of improved survival and population aging. According to related statistical data, valvular diseases affected more than 40 million people worldwide in 2019, with an incidence of 2.8 million per year, which is still growing rapidly. − As a type of complex progressive diseases, valvular disease are featured with a highly complicated and regulated pathological process. It raises great concerns for mechanism studies, involving hemodynamics, hemorheology, etc., and subsequent pharmaceutical development, therapeutics, etc. − The construction of an in vitro model that enables visualization and quantitative analysis and is tunable for bio-mimicking progressive pathological valve states should be able to facilitate the investigation.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Valve-Adjustable Optofluidic Bio-Imaging Platform for Progressive Stenosis Investigation

Liu

et al. 2023

ACS Sens.

View full text Add to dashboard Cite

The clinical evidence has proven that valvular stenosis is closely related to many vascular diseases, which attracts great academic attention to the corresponding pathological mechanisms. The investigation is expected to benefit from the further development of an in vitro model that is tunable for biomimicking progressive valvular stenosis and enables accurate optical recognition in complex blood flow. Here, we develop a valve-adjustable optofluidic bio-imaging recognition platform to fulfill it. Specifically, the bionic valve was designed with in situ soft membrane, and the internal air-pressure chamber could be regulated from the inside out to bio-mimic progressive valvular stenosis. The developed imaging algorithm enhances the recognition of optical details in blood flow imaging and allows for quantitative analysis. In a prospective clinical study, we examined the effect of progressive valvular stenosis on hemodynamics within the typical physiological range of veins by this way, where the inhomogeneity and local enhancement effect in the altered blood flow field were precisely described and the optical differences were quantified. The effectiveness and consistency of the results were further validated through statistical analysis. In addition, we tested it on fluorescence and noticed its good performance in fluorescent tracing of the clotting process. In virtue of theses merits, this system should be able to contribute to mechanism investigation, pharmaceutical development, and therapeutics of valvular stenosis-related diseases.

show abstract

Section: Resultsmentioning

confidence: 74%

Section: ■ Materials and Methodsmentioning

confidence: 66%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Valve-Adjustable Optofluidic Bio-Imaging Platform for Progressive Stenosis Investigation

Liu

et al. 2023

ACS Sens.

View full text Add to dashboard Cite

show abstract

Shear‐Responsive Drug Delivery Systems in Medical Devices: Focus on Thrombosis and Bleeding

Shirejini

Carberry

Alt

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide. Blood‐contacting medical devices provide critical support for patients with severe respiratory and/or cardiac failure. High shear stress zones and non‐biocompatible circuit can increase the risk of thrombus formation in patients. These thrombi restrict blood flow through the circuits and travel to the lungs and brain, creating significant consequences. Antithrombotic drugs are used to lower this risk, but they also raise the incidence of bleeding problems. This article explores the delicate balance between thrombosis and bleeding in medical devices by examining platelet activation and thrombosis formation under shear stress. The feasibility of a shear‐responsive nanomedicine‐based drug delivery system has been explored as a potential approach for targeted administration of antithrombotic medications to lower systemic drug levels and reduce the bleeding risk. Furthermore, the lack of in vitro platforms to investigate the biological behavior of antithrombotic nanoparticles is impeding their clinical translation. As a result, microfluidic technology offers a platform for investigating nanoparticle behavior in vitro and linking it to their performance in vivo. Finally, the challenges and factors that affect the functionality, stability, and circulation time of liposomal drugs are investigated to improve their efficacy for targeted drug administration in medical devices.

show abstract

Reagent‐Free Covalent Immobilization of Biomolecules in a Microfluidic Organ‐On‐A‐Chip

Ashok,

Singh,

Jiang

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Microfluidic systems have become integral for lab‐on‐a‐chip and organ‐on‐a‐chip applications across numerous disciplines. These systems, typically fabricated using polydimethylsiloxane (PDMS) chips on glass substrates, lack the bioactivity required for such applications. To overcome this, biomolecules are immobilized using either oxygen (O2) plasma treatment or chemical reagents like amino silanes. However, O2 plasma treatments are unstable and cannot covalently immobilize biomolecules, while wet‐chemistry approaches are toxic, time‐consuming, and expensive. A novel microfluidic platform that combines two plasma surface treatments: Plasma‐activated coating (PAC) and atmospheric pressure plasma jet (APPJ), to enable reagent‐free covalent immobilization of biomolecules is described here. These surface treatments, unlike O2 plasma, covalently immobilized fibronectin on PDMS and glass, and significantly improved endothelial cell attachment and proliferation. By combining PAC and APPJ, a hybrid microfluidic platform with equivalent bond strength to standard O2 plasma devices, but with significantly enhanced endothelial cell growth in and artery‐on‐a‐chip model, is developed. This platform is also amenable to high‐shear applications such as coronary shear, with endothelial cells aligning with flow, as seen in human arteries. By providing reagent‐free covalent immobilization of biomolecules within a microfluidic system, this technology has the potential to radically improve organ‐on‐a‐chip development as well as lab‐on‐a‐chip systems, point‐of‐care diagnostics, and sensors.

show abstract

Novel Movable Typing for Personalized Vein‐Chips in Large Scale: Recapitulate Patient‐Specific Virchow's Triad and its Contribution to Cerebral Venous Sinus Thrombosis

Cited by 9 publications

References 56 publications

Valve-Adjustable Optofluidic Bio-Imaging Platform for Progressive Stenosis Investigation

Valve-Adjustable Optofluidic Bio-Imaging Platform for Progressive Stenosis Investigation

Shear‐Responsive Drug Delivery Systems in Medical Devices: Focus on Thrombosis and Bleeding

Reagent‐Free Covalent Immobilization of Biomolecules in a Microfluidic Organ‐On‐A‐Chip

Contact Info

Product

Resources

About